Biocomposites, a company that produces products for use in infection management in bone and soft tissue, has launched its Synicem hip, knee, and shoulder preformed spacers in the U.S.

The antibiotic-loaded, preformed spacers deliver a prolonged local concentration of gentamicin while preserving articular space, limb length, and joint stability during two-stage revision procedures. They are precision engineered for consistency and structural uniformity. They are also sterile and ready to use in under a minute.

The Synicem spacers eliminate the time demands and mechanical risks related to traditional intraoperative molded or handmade spacers, according to the company.

The spacer range is available in a comprehensive range of sizes and styles for case-by-case flexibility. The range includes a choice of Charnley and Müller hip spacer designs, and specific left and right geometries for each knee.

Synicem spacers have been successfully used for over two decades in more than 70 countries.

“I’m delighted that we can now provide U.S. surgeons with SYNICEM preformed antibiotic loaded spacers,” said Biocomposites CEO Michael Harris. “Their precision-engineered uniform structure, reliable local antibiotic delivery and wide size range offer a faster, simpler and more dependable alternative to handmade spacers—making SYNICEM spacers an invaluable tool for infection management in complex joint revisions.”

In October 2024, the company took a minority-share interest in InfectoTest, a biomedical company based in Berlin that is developing innovative point-of-care systems for the diagnosis of infectious diseases.